Melanoma cell lines with single resistance to Vemurafenib (BRAF inhibitor) and double resistance to Vemurafenib/Selumetinib (MEK inhibitor)exhibit increased glutamine uptake and NH4+ production without changes in glucose uptake (158). Here, BRAF is linked to melanoma.